Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SINE006 plus organic calcium in children with idiopathic short stature
ChiCTR2500111249Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of bifidobacterium longum subsp. infantis SINE006 in Idiopathic Short Stature (ISS) (3 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Inter-group height SDS difference. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
bifidobacterium longum subsp. infantis SINE006
03
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on ChiCTR2500111249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111249.